vs

Side-by-side financial comparison of Dexcom (DXCM) and MERCURY GENERAL CORP (MCY). Click either name above to swap in a different company.

MERCURY GENERAL CORP is the larger business by last-quarter revenue ($1.5B vs $1.3B, roughly 1.2× Dexcom). Dexcom runs the higher net margin — 21.2% vs 13.2%, a 8.0% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 12.4%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 9.8%).

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

Mercury General Corporation is a multiple-line insurance organization that offers personal automobiles, homeowners, renters, and business insurance. Mercury's primary focus is automobiles and homeowners' insurance.

DXCM vs MCY — Head-to-Head

Bigger by revenue
MCY
MCY
1.2× larger
MCY
$1.5B
$1.3B
DXCM
Growing faster (revenue YoY)
DXCM
DXCM
+9.2% gap
DXCM
21.6%
12.4%
MCY
Higher net margin
DXCM
DXCM
8.0% more per $
DXCM
21.2%
13.2%
MCY
Faster 2-yr revenue CAGR
DXCM
DXCM
Annualised
DXCM
12.0%
9.8%
MCY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DXCM
DXCM
MCY
MCY
Revenue
$1.3B
$1.5B
Net Profit
$267.3M
$202.5M
Gross Margin
62.9%
99.7%
Operating Margin
25.6%
16.2%
Net Margin
21.2%
13.2%
Revenue YoY
21.6%
12.4%
Net Profit YoY
153.6%
100.4%
EPS (diluted)
$0.67
$3.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DXCM
DXCM
MCY
MCY
Q1 26
$1.3B
Q4 25
$1.3B
$1.5B
Q3 25
$1.2B
$1.6B
Q2 25
$1.2B
$1.5B
Q1 25
$1.0B
$1.4B
Q4 24
$1.1B
$1.4B
Q3 24
$994.2M
$1.5B
Q2 24
$1.0B
$1.3B
Net Profit
DXCM
DXCM
MCY
MCY
Q1 26
$267.3M
Q4 25
$267.3M
$202.5M
Q3 25
$283.8M
$280.4M
Q2 25
$179.8M
$166.5M
Q1 25
$105.4M
$-108.3M
Q4 24
$151.7M
$101.1M
Q3 24
$134.6M
$230.9M
Q2 24
$143.5M
$62.6M
Gross Margin
DXCM
DXCM
MCY
MCY
Q1 26
62.9%
Q4 25
62.9%
99.7%
Q3 25
60.5%
99.8%
Q2 25
59.5%
99.8%
Q1 25
56.9%
99.7%
Q4 24
58.9%
99.7%
Q3 24
59.7%
99.8%
Q2 24
62.4%
99.8%
Operating Margin
DXCM
DXCM
MCY
MCY
Q1 26
25.6%
Q4 25
25.6%
16.2%
Q3 25
20.1%
22.1%
Q2 25
18.4%
14.0%
Q1 25
12.9%
-10.2%
Q4 24
17.0%
9.0%
Q3 24
15.3%
18.8%
Q2 24
15.7%
5.8%
Net Margin
DXCM
DXCM
MCY
MCY
Q1 26
21.2%
Q4 25
21.2%
13.2%
Q3 25
23.5%
17.7%
Q2 25
15.5%
11.3%
Q1 25
10.2%
-7.8%
Q4 24
13.6%
7.4%
Q3 24
13.5%
15.1%
Q2 24
14.3%
4.8%
EPS (diluted)
DXCM
DXCM
MCY
MCY
Q1 26
$0.67
Q4 25
$0.67
$3.66
Q3 25
$0.70
$5.06
Q2 25
$0.45
$3.01
Q1 25
$0.27
$-1.96
Q4 24
$0.37
$1.82
Q3 24
$0.34
$4.17
Q2 24
$0.35
$1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DXCM
DXCM
MCY
MCY
Cash + ST InvestmentsLiquidity on hand
$917.7M
Total DebtLower is stronger
$575.0M
Stockholders' EquityBook value
$2.7B
$2.4B
Total Assets
$6.3B
$9.6B
Debt / EquityLower = less leverage
0.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DXCM
DXCM
MCY
MCY
Q1 26
$917.7M
Q4 25
$917.7M
Q3 25
$1.8B
Q2 25
$1.2B
Q1 25
$904.9M
Q4 24
$606.1M
Q3 24
$621.2M
Q2 24
$939.2M
Total Debt
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
$575.0M
Q3 25
Q2 25
Q1 25
Q4 24
$575.0M
Q3 24
Q2 24
Stockholders' Equity
DXCM
DXCM
MCY
MCY
Q1 26
$2.7B
Q4 25
$2.7B
$2.4B
Q3 25
$2.7B
$2.2B
Q2 25
$2.6B
$2.0B
Q1 25
$2.3B
$1.8B
Q4 24
$2.1B
$1.9B
Q3 24
$2.0B
$1.9B
Q2 24
$2.4B
$1.6B
Total Assets
DXCM
DXCM
MCY
MCY
Q1 26
$6.3B
Q4 25
$6.3B
$9.6B
Q3 25
$7.5B
$9.4B
Q2 25
$7.3B
$9.1B
Q1 25
$6.8B
$9.0B
Q4 24
$6.5B
$8.3B
Q3 24
$6.4B
$8.2B
Q2 24
$6.8B
$7.7B
Debt / Equity
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
0.24×
Q3 25
Q2 25
Q1 25
Q4 24
0.30×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DXCM
DXCM
MCY
MCY
Operating Cash FlowLast quarter
$287.9M
Free Cash FlowOCF − Capex
$273.9M
FCF MarginFCF / Revenue
17.8%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
1.42×
TTM Free Cash FlowTrailing 4 quarters
$1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
$294.0M
$287.9M
Q3 25
$659.9M
$496.4M
Q2 25
$303.0M
$371.6M
Q1 25
$183.8M
$-68.7M
Q4 24
$301.4M
$248.3M
Q3 24
$199.5M
$318.1M
Q2 24
$279.4M
$278.0M
Free Cash Flow
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
$192.1M
$273.9M
Q3 25
$579.4M
$479.5M
Q2 25
$208.9M
$357.2M
Q1 25
$96.8M
$-81.9M
Q4 24
$176.8M
$236.0M
Q3 24
$88.3M
$306.2M
Q2 24
$213.3M
$266.5M
FCF Margin
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
15.3%
17.8%
Q3 25
47.9%
30.3%
Q2 25
18.1%
24.2%
Q1 25
9.3%
-5.9%
Q4 24
15.9%
17.3%
Q3 24
8.9%
20.0%
Q2 24
21.2%
20.4%
Capex Intensity
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
8.1%
0.9%
Q3 25
6.7%
1.1%
Q2 25
8.1%
1.0%
Q1 25
8.4%
0.9%
Q4 24
11.2%
0.9%
Q3 24
11.2%
0.8%
Q2 24
6.6%
0.9%
Cash Conversion
DXCM
DXCM
MCY
MCY
Q1 26
Q4 25
1.10×
1.42×
Q3 25
2.33×
1.77×
Q2 25
1.69×
2.23×
Q1 25
1.74×
Q4 24
1.99×
2.46×
Q3 24
1.48×
1.38×
Q2 24
1.95×
4.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons